ClinicalTrials.gg
CompletedNCT05655793TearADUpdated Oct 20, 2026

The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis

An observational study in Alzheimer Disease, sponsored by Maastricht University Medical Center. Completed at 2 sites in Netherlands. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Maastricht University Medical Center · Observational

How we know

Updated Oct 20, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Alzheimer Disease with a site in Netherlands — 16 open to participants now, 27 under way, 9 of them phase 3. Alzheimer Disease · Netherlands.

Enrollment
11th of 14
200 · median 502
Started
2022
with 11 others
Observational
14 of 133
3 open now
Registered
109th of 133
by date
Lead sponsor
5 of 133
Maastricht University Medical Center

Among the 133 studies in Alzheimer Disease with a site in Netherlands, this one is the 11th largest by enrollment of the 14 observational ones that give a count, is one of 12 that started in 2022, is one of 14 observational ones, and was the 109th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

16 of the 133 studies in Alzheimer Disease with a site in Netherlands are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Alzheimer Disease with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this observational longitudinal study is to investigates whether tear fluid is a non-invasive source of biomarkers for Alzheimer's disease. The main aim of the study is to evaluate diagnostic accuracy measures (sensitivity and specificity) of tear and retinal biomarkers to discriminate individuals with and without neurodegeneration.

Tear fluid from participants will be collected non-invasively with Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes. Additionally, standard, ultra-wide field and cross-sectional retinal images will be obtained.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Tear Fluid
  • Retinal imaging
  • Biomarkers
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The patients will be selected from the population that visit the memory clinic and are willing to participate in scientific research.

Eligibility criteria

Inclusion Criteria (healthy controls):

  • Available CSF, PET, CT or MRI data to evaluate the presence/absence of neurodegeneration (preferably within 1 year of inclusion in this study)
  • Absence of cognitive complaints or treatment and did not seek help for cognitive complaints in the past
  • score 26-30 at baseline
  • Age > 50 years
  • Available for follow-up (up to 24 months)
  • Written obtained and documented

Inclusion criteria (patients):

  • Available CSF, PET, CT or MRI data to evaluate the presence/absence of neurodegeneration (preferably within 1 year of inclusion in this study)
  • Available for follow-up (up to 24 months)
  • Written informed consent obtained and documented
  • Capable of giving informed consent themselves (MMSE score > 17/30)

Exclusion Criteria (all subjects):

  • Ocular conditions that could influence tear biochemical parameters (including eye infection, eye inflammation, eye surgery within the last 28 days or other acute eye conditions)
  • Neurological or systemic chronic conditions known to interfere with retinal thickness (e.g., glaucoma, diabetes mellitus)
  • Ocular conditions interfering with optical coherence tomography (OCT) quality/retinal thickness: e.g. severe cataract, age-related macular degeneration, and glaucoma
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • With Neurodegeneration

    Includes patients with mild cognitive impairment and dementia

    Diagnostic Test: Tear Fluid collection (Schirmer's strip) · Diagnostic Test: Retinal imaging

  • Without Neurodegeneration

    Includes healthy controls and patients with subjective cognitive decline

    Diagnostic Test: Tear Fluid collection (Schirmer's strip) · Diagnostic Test: Retinal imaging

Interventions

  • Diagnostic testTear Fluid collection (Schirmer's strip)

    Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.

  • Diagnostic testRetinal imaging

    The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.

06

What researchers measure

Primary outcomes

  1. Capability of tear biomarkers to discriminate individuals with neurodegeneration from those without neurodegeneration and assess the change in biomarker levels over time.

    Levels of tear biomarkers will be determined from the Schirmer's strips. The biomarker levels will be analysed to see whether they can be discriminate between people with and without neurodegeneration.

    Time frame: Sampling done at t= 0, 1 and 2 years.

Secondary outcomes

  1. The difference in tear biomarker level between patients and controls, and between patient groups and how these differences change over time.

    Additional analysis to see whether tear biomarkers can also discriminate patients from controls and differences inbetween patient groups.

    Time frame: Sampling done at t= 0, 1 and 2 years.

  2. Correlation of biomarker levels in tears, blood and cerebral spinal fluid (CSF).

    This analysis will be done to determine the correlation between biomarkers of different body fluids.

    Time frame: Baseline measurements (t=0) will be used to determine correlation.

  3. Correlation between tear biomarkers and other ocular imaging biomarkers, as well as assessing the change of this correlation over time.

    The correlation between tear biomarkers and ocular imaging biomarkers (e.g. thickness of the retinal nerve fiber layer, retinal vasculature tortuosity) will be analysed.

    Time frame: Imaging done at t= 0, 1 and 2 years.

07

Study locations

2 sites
  • Academic Hospital Maastricht
    Maastricht, Limburg 6229 HX, Netherlands
  • Amsterdam University Medical Center
    Amsterdam, North Holland 1081 HV, Netherlands
08

References and documents

Publications

  • van de Sande N, Ramakers IHGB, Visser PJ, Verhey FRJ, Verbraak FD, Bouwman FH, Berendschot TTJM, Nuijts RMMA, Webers CAB, Gijs M. Tear biomarkers for Alzheimer's disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study. BMC Neurol. 2023 Aug 5;23(1):293. doi: 10.1186/s12883-023-03335-y. PubMed 37543602 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jul 2026, 48 months.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's 48 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jul 2025 → Jul 2026 and completion Jul 2025 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2022
First posted
Dec 19, 2022
StartActual
Jun 9, 2022
Primary completionActual
Jul 1, 2026was Jul 2025
CompletionActual
Sep 10, 2026was Jul 2025
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 20, 2026
Sites
1 site added, 1 site removed
Show site
  • Amsterdam University Medical Center · Amsterdam, Netherlands
Show 1 removed
  • Amsterdam University Medical Center · Amsterdam, Netherlands
Oct 20, 2026
Primary completion
Jul 1, 2025→Jul 1, 2026 (actual)
Oct 20, 2026
Study completion
Jul 1, 2025→Sep 10, 2026 (actual)
Oct 20, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37543602 ↗
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37543602 ↗
    1 site added, 1 site removed
    Show site
    • Amsterdam University Medical Center · Amsterdam, Netherlands
    Show 1 removed
    • Amsterdam University Medical Center · Amsterdam, Netherlands
    Primary completion Jul 1, 2025→Jul 1, 2026 (now actual)
    Study completion Jul 1, 2025→Sep 10, 2026 (now actual)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05655793
Responsible party
Sponsor
First posted
Dec 19, 2022
Start date
Jun 9, 2022
Primary completion
Jul 1, 2026
Completion
Sep 10, 2026
Last update
Oct 20, 2026

Study contacts

Marlies Gijs, PhD
principal investigator · Maastricht University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion